Aspirin strategy for secondary prevention of atherosclerotic cardiovascular diseases: A narrative review

Aspirin is the most used antiplatelet agent for secondary prophylaxis of atherosclerotic cardiovascular diseases. Individual variability in aspirin responsiveness has been widely reported. The current recommendations do not take these variations into consideration. Current guidelines recommend 75–100 mg of once-daily aspirin in all patients for secondary prevention. However, “one-dose-fits-all” may not be the appropriate aspirin dosing strategy. Based on our review, we suggest that patients with inadequate aspirin responsiveness are at increased risk of recurrent cardiovascular events. Noncompliance is the most common cause of poor aspirin response. Ensuring adequate compliance and avoiding concomitant ingestion of nonaspirin nonsteroidal anti-inflammatory drugs and bedtime ingestion of aspirin can help achieve adequate aspirin-mediated antiplatelet activity. A low-dose, twice-daily regimen is the preferred strategy in “high-risk” groups.

[1]  R. Thachathodiyl,et al.  Personalized allocation of acetylsalicylic acid therapy for secondary prevention of coronary artery disease , 2022, Frontiers in Cardiovascular Medicine.

[2]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[3]  E. Grove,et al.  Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis , 2019, Platelets.

[4]  Sara A Harper,et al.  Circadian Rhythms, Exercise, and Cardiovascular Health , 2018, Journal of circadian rhythms.

[5]  Deepak L. Bhatt,et al.  Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. , 2018, Journal of the American College of Cardiology.

[6]  Musa Drini,et al.  Peptic ulcer disease and non-steroidal anti-inflammatory drugs. , 2016, Australian prescriber.

[7]  J. Hirsh,et al.  Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial , 2015, Journal of thrombosis and haemostasis : JTH.

[8]  Jonathan D. Grinstein,et al.  Aspirin Resistance: Current Status and Role of Tailored Therapy , 2012, Clinical cardiology.

[9]  J. Dillinger,et al.  Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. , 2012, American heart journal.

[10]  E. Grove,et al.  Combining aspirin and proton pump inhibitors: for whom the warning bell tolls? , 2012, Expert opinion on drug metabolism & toxicology.

[11]  F. Santilli,et al.  The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes , 2012, Journal of thrombosis and haemostasis : JTH.

[12]  J. Hirsh,et al.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[13]  M. Lordkipanidzé,et al.  Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. , 2011, International journal of cardiology.

[14]  K. Schwartz.  Aspirin Resistance , 2011, The Neurohospitalist.

[15]  J. Dillinger,et al.  24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease , 2010, Thrombosis and Haemostasis.

[16]  A. Kaltoft,et al.  Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. , 2010, JACC: Cardiovascular Interventions.

[17]  K. Barber,et al.  Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients , 2008, Journal of Translational Medicine.

[18]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[19]  P. Hjemdahl,et al.  Dose- and time-dependent antiplatelet effects of aspirin , 2006, Thrombosis and Haemostasis.

[20]  I. Kriszbacher,et al.  Can the time of taking aspirin influence the frequency of cardiovascular events? , 2005, The American journal of cardiology.

[21]  S. Steinhubl,et al.  Variability in response to aspirin: do we understand the clinical relevance? , 2005, Journal of thrombosis and haemostasis : JTH.

[22]  V. Fuster,et al.  Platelet-active drugs : the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[23]  J. Michael Gaziano,et al.  Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs , 2003, Circulation.

[24]  H. Breddin,et al.  Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy , 2003, Advances in therapy.

[25]  L. Wei,et al.  Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.

[26]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[27]  J. White,et al.  Ibuprofen Protects Platelet Cyclooxygenase from Irreversible Inhibition by Aspirin , 1983, Arteriosclerosis.

[28]  A. Knox,et al.  Aspirin-Induced Asthma , 2012, Drugs.

[29]  J. Dalen.  Aspirin resistance: is it real? Is it clinically significant? , 2007, The American journal of medicine.

[30]  G. FitzGerald,et al.  Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.